RBC Capital analyst Leonid Timashev maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) on November 13 and set a price target of $25.00. The company’s shares closed yesterday at $9.15.
Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Edgewise Therapeutics, and Pyxis Oncology. According to TipRanks, Timashev has an average return of -19.7% and a 21.43% success rate on recommended stocks.
NewAmsterdam Pharma Company has an analyst consensus of Moderate Buy, with a price target consensus of $24.50.
See today’s best-performing stocks on TipRanks >>
NAMS market cap is currently $822.4M and has a P/E ratio of -45.37.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NewAmsterdam Pharma Company (NAMS) Company Description:
Frazier Lifesciences Acquisition Corp is a blank check company.
Read More on NAMS:
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
- AbbVie upgraded, Cisco downgraded: Wall Street’s top analyst calls
- NewAmsterdam Pharma initiated with an Outperform at RBC Capital
- NewAmsterdam announces appointment of Somaiya as CFO
- NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
